Future Trends In RNAi Drug Delivery

Wed, 03/28/2012 - 04:33 EDT - Seeking Alpha

By Dan Lukehart:For those interested in RNAi therapeutics, it would be wise to pay attention to every development related to delivery technology. The concept and clinical results behind RNAi are compelling, but perhaps something equally exciting is that there is still room to grow. With human proof of concept demonstrated, RNAi companies can reformulate with new delivery technology and enjoy the benefits. This article will examine next generation LNP delivery the pipeline.LNP technology for indications involved with the liver is the most mature delivery system within RNAi therapeutics. Current LNP (lipid nanoparticle) technology is in its 2nd generation (such as ALN-PCS, ALN-TTR02) which has ~100-fold increased potency and better safety than 1st generation (such as ALN-VSP, ALN-TTR1) offerings.One of the issues with the current 2nd generation LNP is that they have long elimination half-lives in plasma and tissues. It is suspected that they might accumulate over time and lead toComplete Story »

Original article
Login or register to post comments

Tekmira: A Undervalued Pioneer In The Field Of RNAi Therapeutics
By Grant Zeng: Tekmira (TKMR) (TKM-TO) is a development stage biopharmaceutical company focused on the research and development of novel RNA interference (RNAi) therapeutics by utilizing its leading lipid nanoparticle (LNP) delivery technology. Based on this platform technology, Tekmira has built a diversified pipeline with both internal and partnered programs. (click to enlarge)
Alnylam's Drug Technologies Could Be Revolutionary
By David White:Alnylam Pharmaceuticals Inc.’s (ALNY‘s) RNA interference (RNAi) technology is potentially revolutionary. ALNY is using this technology to selectively turn off the expression of certain genes to build a pipeline to address a wide variety of genetically defined, “unmet need” diseases.
Bovie's J-Plasma May Slay The MRSA Dragon (And Other Nasties)
ByAndrew Stephan:The J-Plasma surgical technology from Bovie Medical Corporation (BVX) has recently begun to hit the market.
Alnylam Pharmaceuticals' CEO Presents at Discussion of The Medicines Company and Alnylam Strategic Alliance to Develop and Commercialize ALN-PCS Conference (Transcript)
Alnylam Pharmaceuticals, Inc. (ALNY) Discussion of The Medicines Company and Alnylam Strategic Alliance to Develop and Commercialize ALN-PCS Conference Call February 4, 2013 8:30 am ET Executives Cynthia Clayton – Vice President-Investor Relations John Maraganore – Chief Executive Officer Clive Meanwell – Chairman and Chief Executive Officer, The Medicines Company
Investing In Novel Drug Delivery Ideas
By Peter Geschek:Some drug companies are working on a multitude of new drug delivery ideas. From the investor's point of view three of the more promising ones are: Seattle Genetics (SGEN), Immunogen (IMGN) and Halozyme (HALO).
Pfizer’s ‘virtual’ drug trial could reshape R&D processes
Ever thought about answering one of those “Do you suffer from migraines?” or “Got bunions?” clinical trial ads, but just haven’t had the time or energy to enroll?
Halozyme: It's All in the Delivery
Jason Chew submits: According to Datamonitor, market share among pharmaceutical products is shifting from oral therapeutics to injectibles due to such factors as therapeutic focus, molecule type and lifecycle stage. Drug delivery platforms have always played an important role in drug development.
Healthcare, Technology Converge: Recent Biotech Deals
The Burrill Report submits: By Marie Daghlian
Elan Holds Tight on Selling Drug Tech Unit
The Burrill Report submits: By Michael Fitzhugh
Roche, Biogen Idec Scrap Development of Arthritis Drug: Biotech's Latest Mishaps
The Burrill Report submits: Roche (RHHBY.PK) and Biogen Idec (BIIB) say they will discontinue development of late-stage ocrelizumab in rheumatoid arthritis.

Main menu

Secondary menu

Future Trends In RNAi Drug Delivery

Related

Latest

User login

Our Blog

Markets Map

Follow Us

Secondary menu